Episode
hVIVO order book tops £65m as CEO backs strong H2 recovery
- Published
- Jul 23, 2026
- Duration seconds
- 441
- Processing state
not_requested
Actions
POST https://stenobird.com/v1/public/podcasts/proactive-interviews-for-investors-1457173/episodes/hvivo-order-book-tops-65m-as-ceo-backs-strong-h2-recovery/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/proactive-interviews-for-investors-1457173/hvivo-order-book-tops-65m-as-ceo-backs-strong-h2-recovery.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
hVIVO PLC (AIM: HVO) CEO Yamin 'Mo' Khan joined Proactive's Stephen Gunnion to discuss the company's latest trading update, highlighting a record order book of more than £65 million that supports expectations for a much stronger second half of 2026. Khan explained why first-half revenue of around £16.3 million and a modest adjusted EBITDA loss were always expected, with contract wins weighted towards the second half of the year. He said one of the company's strongest-ever periods of new business, following the launch of its integrated clinical development platform, has extended revenue visibility into 2027 and 2028. The interview also explored a 45% increase in inbound requests for proposals, reflecting growing demand across a broader range of services, including human challenge studies, early-phase clinical trials, laboratory services and consulting. Khan discussed how hVIVO has evolved from a specialist human challenge CRO into a diversified clinical research business capable of delivering end-to-end programmes, while pointing to improving biotech funding conditions as a positive backdrop for future growth. For more interviews and market insights, visit the Proactive YouTube channel. Don't forget to like this video, subscribe to the channel and enable notifications so you never miss future updates. Read Proactive's Editorial Policy here: https://www.proactiveinvestors.co.uk/pages/editorialPolicy #hVIVO #HVO #clinicalresearch #CRO #challengetrials #infectiousdisease #biotech #UKstocks #smallcap #investing